Bracketing approach for multiple strenght product EMA [Regulatives / Guidelines]

posted by jag009  – NJ, 2021-07-06 21:19 (1102 d 21:21 ago) – Posting: # 22462
Views: 1,690

Hi all,

For drug product which have multiple strengths (lets say 3), my thinking is to run a BE study comparing highest and lowest strength, and present dissolution similarities between the three strengths + a formulation composition table showing that the formulations are proportional.

Question: What if the product release > 85% within 15 mins? If so then one can't use dissolution to demonstrate similarity.

The product is BCS class 2.



Complete thread:

UA Flag
 Admin contact
23,099 posts in 4,857 threads, 1,646 registered users;
94 visitors (0 registered, 94 guests [including 16 identified bots]).
Forum time: 18:40 CEST (Europe/Vienna)

Imagine if every Thursday your shoes exploded
if you tied them the usual way.
This happens to us all the time with computers,
and nobody thinks of complaining.    Jef Raskin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz